Drugs / ULSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07160205 | Jan 2026 → Sep 2028 expected | idiopathic inflammatory myopathy | Restem, LLC. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ULSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07160205 ↗ |
| Modality | Cell therapy | “umbilical cord lining-derived stem cell (ULSC) product” NCT07160205 ↗ |
| Route | Intravenous | “through IV infusion” NCT07160205 ↗ |